About Concert AI
Concert AI is a company based in Boston (United States) founded in 2018. Concert AI has raised $300 million across 2 funding rounds from investors including SymphonyAI, Sixth Street and Maverick Ventures. The company has 550 employees as of April 02, 2024. Concert AI has completed 1 acquisition, including CancerLinQ. Concert AI offers products and services including Digital Trial Solution, Clinical Trial Optimization, TeraRecon Advanced Visualization, Eureka Clinical AI, and CancerLinQ. Concert AI operates in a competitive market with competitors including Veeva Systems, Definitive Healthcare, Sygnature Discovery, ESO and Instem, among others.
- Headquarter Boston, United States
- Employees 550 as on 02 Apr, 2024
- Stage Unicorn
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Symphony Concerto India Private Limited
- Date of Incorporation 06 Nov, 2019
- Jurisdiction Bangalore North, Karnataka, India
-
Annual Revenue
$8.76 M (USD)64.22as on Mar 31, 2022
-
Net Profit
$864.6 K (USD)66.72as on Mar 31, 2022
-
EBITDA
$1.33 M (USD)59.39as on Mar 31, 2022
-
Total Equity Funding
$300 M (USD)
in 2 rounds
-
Latest Funding Round
$150 M (USD), Series C
Mar 29, 2022
-
Investors
SymphonyAI
& 4 more
-
Employee Count
550
as on Apr 02, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Concert AI
Concert AI offers a comprehensive portfolio of products and services, including Digital Trial Solution, Clinical Trial Optimization, TeraRecon Advanced Visualization, Eureka Clinical AI, and CancerLinQ.
Platform for accelerating oncology clinical trials using AI.
Services to enhance trial data analysis and patient outcomes.
Tool for advanced medical imaging and data interpretation.
AI system for clinical insights in oncology research.
Platform aggregating oncology data for research purposes.
People of Concert AI
Unlock access to complete
Unlock access to complete
Software Development Team
44 people
Leadership Team
38 people
Data Analysis and Operations Team
30 people
Senior Team
24 people
Clinical Team
8 people
Product Management Team
7 people
Project Team
5 people
Operations Team
5 people
Unlock access to complete
Funding Insights of Concert AI
Concert AI has successfully raised a total of $300M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $150 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Concert AI
Concert AI has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SymphonyAI, Sixth Street and Maverick Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and debt investments are managed across multiple sectors.
|
Locked | Locked | Locked | |
|
Early-stage tech and life-sciences firms are funded across the US.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Concert AI
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Concert AI
Concert AI has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CancerLinQ.
Investment portfolio details for Concert AI
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer professionals and researchers are connected through a data platform.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Concert AI
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Concert AI
Detailed financials for Concert AI
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Concert Ai Comparisons
Peer comparison for Concert AI
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Concert AI
Concert AI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Veeva Systems, Definitive Healthcare, Sygnature Discovery, ESO and Instem, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based data management solutions for healthcare are provided.
|
|
| Locked | Locked | Locked |
Offers market intelligence and data analytics for healthcare providers and physicians
|
|
| Locked | Locked | Locked |
Services and products for integrated drug discovery are provided.
|
|
| Locked | Locked | Locked |
EHR platform for emergency services is provided.
|
|
| Locked | Locked | Locked |
Software for life science data collection and analysis is provided.
|
|
| Locked | Locked | Locked |
AI powered scientific data management and workflow automation solutions
|
Detailed competitors of Concert AI
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Concert Ai
Complete news archive for Concert AI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Concert AI
Concert AI was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Concert AI is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Jeff Elton is the current CEO of Concert AI.
Concert AI is a funded company, having raised a total of $300M across 2 funding rounds to date.
As of Apr 02, 2024, the latest employee count at Concert AI is 550.
Annual revenue of Concert AI is $8.76M as on Mar 31, 2022.
Concert AI was founded in 2018 and is based in Boston, United States. An AI-based platform is operated for oncology research, encompassing data on lab results, practice visits, tumor observations, vitals, pain biometrics, medications, diagnosis states, budgets, costs, and comorbidities. Real-time patient matching to clinical trials is facilitated, alongside collaborations with biopharma companies in the sector.
Concert AI's top competitors include Veeva Systems, Dotmatics and Definitive Healthcare.
Concert AI offers Digital Trial Solution, Clinical Trial Optimization, TeraRecon Advanced Visualization, Eureka Clinical AI, and CancerLinQ.
Concert AI has made 1 acquisition, including CancerLinQ.
Concert AI has 5 investors. Key investors include SymphonyAI, Sixth Street, Maverick Ventures, AllianceBernstein, and Declaration Partners.
The valuation of Concert AI is $1.9B as of Mar 2022.